



NATIONAL
QUALITY FORUM

National Consensus Standards for Cardiovascular Conditions

***Off-Cycle Standing Committee Meeting
February 2, 2017***

*Melissa Marinelarena, RN, MPA, Senior Director
Wunmi Isijola, MPH, Managing Director
Donna Logan, MPH, Project Manager*

NQF Staff

- **Project staff**

- *Melissa Marinelarena, RN, MPA, Senior Director*
- *Wunmi Isijola, MPH, Managing Director*
- *Donna Logan, MPH, Project Manager*

- **NQF Quality Measurement leadership staff**

- *Elisa Munthali, Vice President*
- *Marcia Wilson, Senior Vice President*

Introductions & Disclosures of Interest

Cardiovascular Standing Committee

- **Mary George, MD, MSPH, FAHA (Co-chair)**
- **Sana Al-Khatib, MD, MHS**
- **Carol Allred, BA**
- **Linda Briggs, DNP**
- **Leslie Cho, MD**
- **Joseph Cleveland, MD**
- **Michael Crouch, MD, MSPH, FAAFP**
- **Elizabeth DeLong, PhD**
- **Kumar Dharmarajan, MD, MBA**
- **William Downey, MD**
- **Brian Forrest, MD**
- **Ellen Hillegass, PT, EdD, CCS, FAACVPR, FAPTA**
- **Thomas Kottke, MD, MSPH (Co-chair)**
- **Thomas James, MD**
- **Charles Mahan, PharmD, PhC, RPh**
- **Joel Marrs, PharmD, FNLA, BCPS, CLS**
- **Gerard Martin, MD, FAAP, FACC, FAHA**
- **Kristi Mitchell, MPH**
- **Gary Puckrein, PhD**
- **Nicholas Ruggiero, MD, FACP, FACC, FSCAI, FSVM, FCPP**
- **Jason Spangler, MD, MPH, FACPM**
- **Mladen Vidovich, MD**
- **Daniel Waxman, MD, PhD**

Roles of the Standing Committee

During the Evaluation Meeting

- Act as a proxy for the NQF multi-stakeholder membership
- Work with NQF staff to achieve the goals of the project
- Evaluate each measure against each criterion
 - *Indicate the extent to which each criterion is met and rationale for the rating*
- Make recommendations regarding endorsement to the NQF membership
- Oversee portfolio of Cardiovascular measures

Types of Electronic Clinical Measures (eCQMs)

Four Submission Paths for eCQMs

- **De Novo** – A newly developed eCQM that is not based on an existing chart-abstracted measure, and has not been endorsed by NQF is considered a De Novo measure.
- **“Legacy” eCQM** – A new eCQM version of an NQF endorsed measure, that is currently in use in a federal accountability program, and has been respecified from a chart-abstracted/registry format.
- **Respecified eMeasures** – A currently chart-abstracted measure, that has never been endorsed by NQF, that is being respecified into an eCQM.
- **Approval for Trial Use** – Approval for Trial Use is not endorsement, and is only appropriate for newly developed eCQMS that have not been specified from an existing measure and are not in use in federal programs. Testing for reliability and validity is not required, but there are specific qualifications for this program.

eMeasure Approval for Trial Use Evaluation and Endorsement Overview

Evaluation and Endorsement Overview

- Trial Use designation expires within 3 years if not submitted for endorsement
- If submitted, the developer has two options for evaluation and endorsement:
 - *Option 1: Submit & evaluate only Scientific Acceptability including final specifications and testing*
 - *Option 2: Submit & evaluate all criteria*
- If submitted for endorsement ≥ 3 years after approved for trial use, measure is evaluated on all criteria

Questions?

Consideration of Candidate Measure

Measure #2764: Fixed-dose Combination of Hydralazine and Isosorbide Dinitrate Therapy for Self-identified Black or African American Patients with Heart Failure and LVEF <40% on ACEI or ARB and Beta-blocker Therapy (NMQF)

- **Measure Type: eMeasure**
- **Description:** Percentage of patients aged 18 years and older with a diagnosis of heart failure (HF) and a current or prior ejection fraction (EF) <40% who are self-identified Black or African Americans and receiving ACEI or ARB and Beta-blocker therapy who were prescribed a fixed-dose combination of hydralazine and isosorbide dinitrate seen for an office visit in the measurement period in the outpatient setting or at each hospital discharge.

Measure #2764: Fixed-dose Combination of Hydralazine and Isosorbide Dinitrate Therapy for Self-identified Black or African American Patients with Heart Failure and LVEF <40% on ACEI or ARB and Beta-blocker Therapy (NMQF)

- **Summary of Prior Review during the Cardiovascular 2015-2016 Project**
 - **Evidence: High-6; Moderate-10; Low-1**
 - **Performance Gap: High-6; Moderate-10; Low-1**
 - **Specifications: High-3; Moderate-12; Low-2**
 - **Feasibility: High-1; Moderate-14; Low-2**
 - **Use and Usability: High-2; Moderate-9; Low-6**
 - **Standing Committee Recommendation for Approval for Trial Use: Yes-14; No-3**

Measure #2764: Fixed-dose Combination of Hydralazine and Isosorbide Dinitrate Therapy for Self-identified Black or African American Patients with Heart Failure and LVEF <40% on ACEI or ARB and Beta-blocker Therapy (NMQF)

■ **Lead Discussants:**

- *Thomas Kottke*

- *Mary George*

■ **Criteria Under Review Today:**

- *Reliability*

- *Validity*

- *Overall Suitability*

NQF Member & Public Comment

Next Steps & Project Contact Info

- **Next Steps:**

- *Public and Member Comment Period: 2/22/17 - 3/8/17*
- *Post-Comment Call: March 31, 2017 from 2:00-3:00pm EST*

- Email: cardiovascular@qualityforum.org

- NQF Phone: 202-783-1300

- Project page:

http://www.qualityforum.org/Project_Pages/cardiovascular.aspx

- SharePoint site:

<http://share.qualityforum.org/Projects/cardiovascular/SitePages/Home.aspx>

Adjourn